GSM城市站国家站国际

JAMA ATTAIN-OSA 两项试验共 712 人:口服 orforglipron 52 周使睡眠呼吸暂停指数多降约 12 至 13 次/小时,尚未获批该适应症

2026-11-15 · 医疗 · GSM News
JAMA ATTAIN-OSA 两项试验共 712 人:口服 orforglipron 52 周使睡眠呼吸暂停指数多降约 12 至 13 次/小时,尚未获批该适应症

《美国医学会杂志》(JAMA)2026 年 11 月 9 日在线发表 ATTAIN-OSA 两项三期随机临床试验结果,并于美国心脏协会科学年会同步报告:每日一次口服药 orforglipron 在 52 周内显著降低中重度阻塞性睡眠呼吸暂停(OSA)合并超重或肥胖成人的呼吸暂停低通气指数(AHI)。该药由礼来公司开发,目前获批用途为体重管理,睡眠呼吸暂停适应症尚未获批;礼来计划在 2026 年底前向美国食品药品管理局提交该用途申请。

两项试验共随机 712 人:试验 1 纳入 363 名未使用正压通气(PAP)治疗者,试验 2 纳入 349 名已使用 PAP 至少 3 个月者;受试者均为中重度 OSA、体重指数不低于 27,且无 1 型或 2 型糖尿病。试验在 9 个国家 66 个地点开展,为双盲、安慰剂对照设计,主要终点评估至第 52 周。

第 52 周 AHI 变化:试验 1 中 orforglipron 组下降 17.8 次/小时,安慰剂组下降 4.5 次/小时,组间差异为多降 13.2 次/小时;试验 2 中分别为下降 17.3 与 5.3 次/小时,差异为多降 12.0 次/小时。7 项关键次要终点中有 6 项显著优于安慰剂。最常见不良事件为胃肠道事件:试验 1 中用药组 181 人中有 123 人(68.0%)、安慰剂组 182 人中有 68 人(37.4%);试验 2 中分别为 177 人中有 125 人(70.6%)与 172 人中有 63 人(36.6%)。

JAMA 摘要注明局限:试验仅持续 52 周,多数受试者为重度 OSA,种族与族裔多样性较低,糖尿病患者、体重指数低于 27 者与轻度 OSA 患者被排除,更长期与更广泛人群的研究仍有需要。本稿只报道试验事实与监管状态,不作个体诊疗或用药建议。

JAMA ATTAIN-OSA: Oral Orforglipron Cut Apnea-Hypopnea Index by an Extra 12 to 13 Events an Hour in 712 Adults Over 52 Weeks

Two phase 3 randomized trials in the ATTAIN-OSA program, published online in JAMA on November 9, 2026, and presented at the American Heart Association Scientific Sessions, found that once-daily oral orforglipron significantly reduced the apnea-hypopnea index (AHI) over 52 weeks in adults with moderate to severe obstructive sleep apnea (OSA) and obesity or overweight. Orforglipron, developed by Eli Lilly and Company, is approved for weight management; it is not approved for sleep apnea, and Lilly plans to submit it to the U.S. Food and Drug Administration for that use by the end of 2026.

The two multicenter, double-blind, placebo-controlled trials randomized 712 patients in total: 363 in trial 1, who were not receiving positive airway pressure (PAP) therapy, and 349 in trial 2, who had been receiving PAP for at least 3 months. Participants had moderate to severe OSA and a body mass index of at least 27, without type 1 or type 2 diabetes. The trials ran at 66 sites in nine countries, with outcomes assessed from baseline to week 52.

At week 52, AHI fell by 17.8 events an hour with orforglipron versus 4.5 with placebo in trial 1, a difference of minus 13.2 events an hour; in trial 2 the falls were 17.3 versus 5.3 events an hour, a difference of minus 12.0. Six of seven key secondary endpoints significantly favored orforglipron. Gastrointestinal events were most common: in trial 1, 123 of 181 patients (68.0%) on orforglipron versus 68 of 182 (37.4%) on placebo; in trial 2, 125 of 177 (70.6%) versus 63 of 172 (36.6%).

JAMA's summary notes the trials lasted only 52 weeks, most participants had severe OSA, racial and ethnic diversity was low, and patients with diabetes, a body mass index below 27, or mild OSA were excluded, so longer-term studies in broader populations are needed. This report presents trial facts and regulatory status only and makes no individual treatment recommendation.

来源:美国医学会杂志

发布:GSM·美国(发布链接)

图片来源:图中是一台持续正压通气(CPAP)呼吸机及面罩。图源:Wikimedia Commons(File:CPAP machine.jpg),作者 Mnalis,授权 CC0 1.0。

GSM Global · 本篇英文版 English edition of this story

本频道最新更多 ›

← 返回医疗 全部新闻 关于我们

GSM首页白宫联邦加州南加各州社会军事司法选举世界中国城市站国家站移民宣传专题视频直播放映厅电子书电子报科技金融教育医疗影视音乐体育文旅时尚演出活动娱乐游戏生活美食户外交通汽车地产保险儿童长者留学生宠物信仰非盈利机构